Carlo Bosi

MD, resident in medical oncology @SanRaffaeleMI. Graduate of University of Milan Medical School.

[Carlo Bosi @CarloBoMD]

💥💥💥Thrilled to share the proof-edited final version of our pan-cancer analysis of #ADC targets and potential predictors of response 👉https://t.co/eo27Mw9eyE
Key points below 👇

[Carlo Bosi @CarloBoMD]

🧵 1/10 🔬 Out on European Journal Of Cancer “Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response” DOI:https://t.co/Qf7U41jrse…
If you want to know more about ADCs 👇👇👇

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Giampaolo Bianchini @BianchiniGP]

🔥 Trop 2 pan-cancer, normal tissue and single cell expression analysis just out in NPJ precision oncology

Tissue distribution explain on-target off-tumor side effects such as mucositis

Methylation is key regulatory mechanism

More 👇👇👇
@OncoAlert @Larvol
@NaturePortfolio

[Carlo Bosi @CarloBoMD]

Dynamic immune profiling moves center stage: check this out! @DugoMat @BianchiniGP

[Giampaolo Bianchini @BianchiniGP]

🔥 Who truly benefits from immune checkpoint inhibitors in early triple-negative breast cancer (#TNBC)?
Precision immunology is a major unmet need
✅Key finding: on-treatment complement baseline biopsies
Immunity is dynamic, not a snapshot
Link and more 👇👇👇
@Annals_Oncology

[Giampaolo Bianchini @BianchiniGP]

🔥 Who truly benefits from immune checkpoint inhibitors in early triple-negative breast cancer (#TNBC)?
Precision immunology is a major unmet need
✅Key finding: on-treatment complement baseline biopsies
Immunity is dynamic, not a snapshot
Link and more 👇👇👇
@Annals_Oncology

[Giampaolo Bianchini @BianchiniGP]

🔥 Beyond the hype: ADC are advancing faster (🚀) then our clinical strategy (🐌) in breast cancer

Great job @NotiniGiulia

👉 Sometimes advancing faster means leaving something behind

@JavierCortesMD
@OncoAlert

https://t.co/ImNyqn9xsd

[Itai Yanai @ItaiYanai]

Why would anyone want to be a scientist? There are the pleasures of:
1. Having the initial idea or insight,
2. Watching the idea develop into new experiments or a new model, and
3. Telling others.
Martin A. Schwartz also talks about this on the podcast: https://t.co/oZfXaZXsQ4

[Luca Licata, MD @LLicata88]

🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC

We analyzed 5 major trials
👉 Early relapse: up to 83% of all recurrences🤯

1/ 🧵 Why this matters 👇

🔗 Full article: https://t.co/kih7813mKs

[Fondazione Gianni Bonadonna @FondazioneBona1]

Analysis of molecular data from the NA-PHER2 trial, led from Michelangelo researchers identified new biomarkers predictive of response in HER2+/ER+ breast cancer patients receiving targeted treatments
https://t.co/7AKi26WZL7
@BianchiniGP @CarmenCriscit @mauricallari Matteo Dugo

[Maurizio Callari @mauricallari]

📢Our work just published in @NatureComms @NaturePortfolio!
What is driving #response to #targeted #treatments in HER2+ER+ #breastcancer? How is the tumour ecosystem affected by treatment? Find the answers in our paper 👉 https://t.co/NXmOALfJBX
Key points below 👇

[Carlo Bosi @CarloBoMD]

the bare conceptualization and presentation of such a law proposal is a scandal. Hope it will be swiftly rejected

[Matteo Salvini @matteosalvinimi]

✅ Presentata questa mattina alla Camera la proposta di legge della Lega per USCIRE dall’OMS (Organizzazione Mondiale della Sanità), come hanno fatto gli Stati Uniti con Donald Trump.
L’Italia non deve più avere a che fare con un centro di potere sovranazionale - profumatamente finanziato dai contribuenti italiani - che va a braccetto con le multinazionali del farmaco.
Usiamo quei 100 milioni per sostenere i malati in Italia e finanziare i nostri ospedali e medici!

[Giampaolo Bianchini @BianchiniGP]

🔥Impressed by PATINA trial results?
👉 the longest mPFS ever in breast cancer (44 mths)

Unexpected? Not really
- Our study (👇👇) explain the biological rational
- Supportive clinical trials (NA-PHER2, PERTAIN)

❗️CLEOPATRA trial did not allow ET maintenance

@SABCSSanAntonio

[Marco Barreca @MarcoBarreca3]

🎉 I’m thrilled to announce that our new scientific article has been published in @Nature_NPJ Precision Oncology! In this study, we developed and validated the Breast Cancer Purity Score (#BCPS). Take a look here:
https://t.co/MfYOyHNQT0

[Prof Lennart Nacke, PhD @acagamic]

How to select your research paradigm

[Carlo Bosi @CarloBoMD]

Do not miss this last paper by our @mariani_m97 💥 💥💥

[Marco Mariani @mariani_m97]

Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.”
#BreastCancerResearch @OncoAlert @SanRaffaeleMI

👇Check out some key insights below

[Carmen Criscitiello @CarmenCriscit]

Fantastic talk by @BianchiniGP at #ASCO2024 : "Does the Target Matter?" re ADCs. Must say, the insights were top-notch! But full disclosure: I might be a bit biased! 😅 #CancerResearch #ADCs

[Yale Cancer Center @YaleCancer]

Dr. Lajos Pusztai @YaleBreast presents the RSClin tool #ASCO24, a new tool developed to provide estimates of recurrence risk and chemotherapy benefit for patients with HR+/HER2- node-negative #breastcancer @OncoAlert @SmilowCancer @YaleMed
https://t.co/Bn3v4ZalLb

[Carlo Bosi @CarloBoMD]

Milestone in neuroscience by a great friend and amazing scientist. Congrats @a_marinvargas 🎉🎉🎉

[Alessandro Marin Vargas @a_marinvargas]

𝗙𝗶𝗻𝗮𝗹𝗹𝘆 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 @CellCellPress !

How does the brain processes proprioceptive information?🧠

We use a task-driven modeling approach by combining biomechanics 🦾 and neural network modeling💻 to investigate different hypotheses. 1/N

https://t.co/sw74g6uIM6

[Niklas Klümper @niklas_kluemper]

Very exciting abstract presentation at @AACR in San Diego: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

🔍This innovative bispecific Trop2/Nectin4 targeting ADC basically mimics the combination of the Ph1 DAD trial (EV+SG in previously treated mUC), which achieved an exciting ORR of 70 %! 🔥 @Annals_Oncology @myESMO https://t.co/qckbiYA7tD

Combining ADC with different targets, especially when target gene expression is heterogeneous (like membranous Nectin4), a seems to be a valuable way to improve outcomes - what do you think?

@Markuseckstein3 @ViktorGruenwald @PGrivasMDPhD @tompowles1 @drenriquegrande @PTarantinoMD @amerseburger @urotoday @Uroweb @Uromigos @imedverse

[Raffaele Colombo @raffcolo]

Final version of our paper is out! @ZymeworksInc

https://t.co/hop2a5RgYz

Kudos to @MCT_AACR production team and editors, especially @DanielleLarge2

(Bonus: summary of all the TOPO1i ADCs in clinical development up to January 1st, 2024)

[Carlo Bosi @CarloBoMD]

Great work by our @NotiniGiulia 💥💥
Key insights on nausea management while on T-DXd

[Giulia Notini @NotiniGiulia]

1/4
📢Calling all T-Dxd prescribers!💉

Out now in @FrontOncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA)

https://t.co/Z5vDBmyrTz

@LLicata88 @BianchiniGP
🧵👇🏻👇🏻